Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
109.68
-2.02 (-1.81%)
Jul 21, 2025, 4:00 PM - Market closed
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $121.46M in the quarter ending March 31, 2025, with 61.95% growth. This brings the company's revenue in the last twelve months to $432.16M, up 72.16% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$432.16M
Revenue Growth
+72.16%
P/S Ratio
12.25
Revenue / Employee
$632,734
Employees
683
Market Cap
5.42B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AXSM News
- 1 day ago - Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - GlobeNewsWire
- 13 days ago - Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewsWire
- 15 days ago - Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. - GlobeNewsWire
- 2 months ago - Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - GlobeNewsWire